MB
VKTX icon

MPM BioImpact’s Viking Therapeutics VKTX Stock Holding History

MPM BioImpact’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-120,982
Closed -$7.66M – 54
2024
Q3 		$7.66M Buy
120,982
+2,022
+2% +$119K 1.15% 28
2024
Q2 		$6.31M Sell
118,960
-31,040
-21% -$2.03M 0.98% 34
2024
Q1 		$12.3M Sell
150,000
-175,284
-54% -$7.8M 1.98% 16
2023
Q4 		$6.05M Buy
325,284
+284
+0.1% +$3.71K 1.42% 26
2023
Q3 		$3.6M Buy
+325,000
New +$4.65M 0.96% 30

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

MPM BioImpact's VKTX Position: Q4 2024 in Review

MPM BioImpact sold out of Viking Therapeutics (VKTX) in Q4 2024, closing a stake of 120,982 shares — an estimated $7.66M sold.

MPM BioImpact first reported a position in VKTX in Q3 2023 and held it in 5 quarters. The position peaked at $12.3M in Q1 2024. 408 funds tracked by Wall St. Rank hold VKTX as of Q4 2024.

  • MPM BioImpact reported no remaining Viking Therapeutics position as of Q4 2024 after selling out during the quarter.
  • MPM BioImpact sold 120,982 Viking Therapeutics shares in Q4 2024, an estimated $7.66M.
  • MPM BioImpact first reported a position in Viking Therapeutics in Q3 2023 and held it in 5 quarters.
  • MPM BioImpact's Viking Therapeutics position peaked at $12.3M in Q1 2024.
  • 408 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2024.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.